Key Insights

Highlights

Treatment Research

3 treatments under study, led by Debrichem

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 4 (1)

Trial Status

Not Yet Recruiting2
Unknown1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07452354Not Yet Recruiting

AI-Based Diabetic Foot Recurrence Cohort

NCT07206862Not ApplicableNot Yet Recruiting

CHEMfoot: DEBRICHEM® in Chronic Diabetic Foot Wounds

NCT06197412Phase 4UnknownPrimary

Multi-center Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot Ulcer

Showing all 3 trials

Research Network

Common Treatments

  • Debrichem1
  • Researchers Predefined Groups Based On Risk Stratification To Formulate Personalized Followup Strategies1
  • Yunnan Baiyao1

Active Sponsors

  • Peking University Third Hospital2
  • DEBx Medical B.V.1

Top Investigators

Related Conditions

  • Diabetic Foot Ulcer Dfu2
  • Diabetic Foot Wounds1
  • Artificial Intelligence Ai In Diagnosis1
  • Diabete Mellitus1

Activity Timeline